NATICK, Mass., European regulators have approved an expanded indication for the Boston Scientific Corporation WATCHMAN ® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

MARLBOROUGH, Mass., May 8, 2020 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the ...

PHOENIX — Abrazo Arizona Heart Hospital in Phoenix last week became the first health center in the state to implant a new device designed to reduce stroke risk. The hospital, which is located on ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Novel Stroke Risk Reduction Option for Indicated Patients with Atrial Fibrillation MARLBOROUGH, Mass., This week, four patients in the United States received the first implants of the Boston ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of patency and device-related thrombus were ...

The Amplatzer Amulet (Abbott) and first-generation Watchman 2.5 (Boston Scientific) devices provide relatively comparable results out to 3 years after left atrial appendage occlusion (LAAO), longer ...

Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial ...

New stroke risk reduction technology designed to advance procedural performance and safety, treat wider range of patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., July 21, 2020 ...